Mozart Therapeutics Raises $25M to Advance Autoimmune Disease Drug MTX-101 with FDA IND Planned for Early 2024

Seattle biotech Mozart Therapeutics secured $25 million to advance MTX-101, its drug candidate for autoimmune gastrointestinal diseases, aiming for FDA IND submission by early 2024. The company, led by CEO Katie Fanning and supported by notable investors, has raised a total of $80 million since its 2020 launch.